Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Allergy, Asthma & Respiratory Disease ; : 84-92, 2021.
Article in English | WPRIM | ID: wpr-913301

ABSTRACT

Purpose@#Contrast media is one of the most common cause of adverse drug reaction (ADR) in adult. However, there was little data reported about differences in ADR ratio and severity among iodinated contrast media (ICM). @*Methods@#Medical records of 627,049 patients who performed computed tomography scan using low-osmolar nonionic iodinated contrast media from January 2015 to December 2018 were retrospectively reviewed. A total of 6 ICMs including iomeprol, iohexol, iopromide, iobitridol, ioversol, and iopamidol were used in this period. The incidence of ADR was compared to their total usage and dosage between each contrast media. @*Results@#The incidence of ADR of iopromide (1.36%) and iomeprol (1.27%) was the highest when compared with the average incidence of 1% of 6 ICMs. Ioversol (0.67%), iohexol, and iobitridol (0.74%) had the lower incidence of ADR. The order of results adjusted by actual administered dosage, the use of premedication, and the prior exposure history of ICMs was similar. The fraction of moderate and severe ADR in overall ADR was slightly different, but not proportional to the incidence of ADR. @*Conclusion@#The incidence of ADR among 6 low-osmolar nonionic ICMs was significantly different when compared by the total number of usage and the total volume of dose. The incidence of ADR varied by nearly 2-fold depending on ICMs. Further study might need to explore the reason for the difference of incidence.

2.
Journal of Rheumatic Diseases ; : 91-94, 2012.
Article in English | WPRIM | ID: wpr-15488

ABSTRACT

Hematologic malignancies and lymphoproliferative disorders have been reported after using tumor necrosis factor-alpha inhibitor in patients suffering from spondyloarthropathy. Previously reported cases were treated by using infliximab and etanercept. Usually, it takes approximately several months for leukemia or lymphoproliferative disorders to occur after the application of those agents. However, we report a case of acute myeloid leukemia that developed after short term usage of adalimumab in a patient suffering from psoriatic arthritis.


Subject(s)
Humans , Antibodies, Monoclonal , Antibodies, Monoclonal, Humanized , Arthritis, Psoriatic , Hematologic Neoplasms , Immunoglobulin G , Leukemia , Leukemia, Myeloid, Acute , Lymphoproliferative Disorders , Receptors, Tumor Necrosis Factor , Spondylarthropathies , Stress, Psychological , Tumor Necrosis Factor-alpha , Adalimumab , Infliximab , Etanercept
SELECTION OF CITATIONS
SEARCH DETAIL